Literature DB >> 18560354

Gene array analysis reveals a common Runx transcriptional programme controlling cell adhesion and survival.

S Wotton1, A Terry, A Kilbey, A Jenkins, P Herzyk, E Cameron, J C Neil.   

Abstract

The Runx genes are important in development and cancer, where they can act either as oncogenes or tumour suppressors. We compared the effects of ectopic Runx expression in established fibroblasts, where all three genes produce an indistinguishable phenotype entailing epithelioid morphology and increased cell survival under stress conditions. Gene array analysis revealed a strongly overlapping transcriptional signature, with no examples of opposing regulation of the same target gene. A common set of 50 highly regulated genes was identified after further filtering on regulation by inducible RUNX1-ER. This set revealed a strong bias toward genes with annotated roles in cancer and development, and a preponderance of targets encoding extracellular or surface proteins, reflecting the marked effects of Runx on cell adhesion. Furthermore, in silico prediction of resistance to glucocorticoid growth inhibition was confirmed in fibroblasts and lymphoid cells expressing ectopic Runx. The effects of fibroblast expression of common RUNX1 fusion oncoproteins (RUNX1-ETO, TEL-RUNX1 and CBFB-MYH11) were also tested. Although two direct Runx activation target genes were repressed (Ncam1 and Rgc32), the fusion proteins appeared to disrupt the regulation of downregulated targets (Cebpd, Id2 and Rgs2) rather than impose constitutive repression. These results elucidate the oncogenic potential of the Runx family and reveal novel targets for therapeutic inhibition.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18560354      PMCID: PMC2562521          DOI: 10.1038/onc.2008.195

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  46 in total

Review 1.  Core-binding factors in haematopoiesis and leukaemia.

Authors:  Nancy A Speck; D Gary Gilliland
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

2.  A full-length Cbfa1 gene product perturbs T-cell development and promotes lymphomagenesis in synergy with myc.

Authors:  F Vaillant; K Blyth; A Terry; M Bell; E R Cameron; J Neil; M Stewart
Journal:  Oncogene       Date:  1999-11-25       Impact factor: 9.867

3.  Runx2: a novel oncogenic effector revealed by in vivo complementation and retroviral tagging.

Authors:  K Blyth; A Terry; N Mackay; F Vaillant; M Bell; E R Cameron; J C Neil; M Stewart
Journal:  Oncogene       Date:  2001-01-18       Impact factor: 9.867

4.  Exogenous cdk4 overcomes reduced cdk4 RNA and inhibition of G1 progression in hematopoietic cells expressing a dominant-negative CBF - a model for overcoming inhibition of proliferation by CBF oncoproteins.

Authors:  J Lou; W Cao; F Bernardin; K Ayyanathan; F J RauscherIII; A D Friedman
Journal:  Oncogene       Date:  2000-05-18       Impact factor: 9.867

5.  ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain.

Authors:  J M Amann; J Nip; D K Strom; B Lutterbach; H Harada; N Lenny; J R Downing; S Meyers; S W Hiebert
Journal:  Mol Cell Biol       Date:  2001-10       Impact factor: 4.272

6.  The common retroviral insertion locus Dsi1 maps 30 kilobases upstream of the P1 promoter of the murine Runx3/Cbfa3/Aml2 gene.

Authors:  Monica Stewart; Nancy MacKay; Ewan R Cameron; James C Neil
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

7.  Ftz modulates Runt-dependent activation and repression of segment-polarity gene transcription.

Authors:  Deborah Swantek; J Peter Gergen
Journal:  Development       Date:  2004-04-21       Impact factor: 6.868

8.  The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia.

Authors:  Bryan Linggi; Carsten Müller-Tidow; Louis van de Locht; Ming Hu; John Nip; Hubert Serve; Wolfgang E Berdel; Bert van der Reijden; Dawn E Quelle; Janet D Rowley; John Cleveland; Joop H Jansen; Pier Paolo Pandolfi; Scott W Hiebert
Journal:  Nat Med       Date:  2002-06-24       Impact factor: 53.440

9.  The Runx3 transcription factor regulates development and survival of TrkC dorsal root ganglia neurons.

Authors:  Ditsa Levanon; David Bettoun; Catherine Harris-Cerruti; Eilon Woolf; Varda Negreanu; Raya Eilam; Yael Bernstein; Dalia Goldenberg; Cuiying Xiao; Manfred Fliegauf; Eitan Kremer; Florian Otto; Ori Brenner; Aharon Lev-Tov; Yoram Groner
Journal:  EMBO J       Date:  2002-07-01       Impact factor: 11.598

10.  Groucho/TLE/R-esp proteins associate with the nuclear matrix and repress RUNX (CBF(alpha)/AML/PEBP2(alpha)) dependent activation of tissue-specific gene transcription.

Authors:  A Javed; B Guo; S Hiebert; J Y Choi; J Green; S C Zhao; M A Osborne; S Stifani; J L Stein; J B Lian; A J van Wijnen; G S Stein
Journal:  J Cell Sci       Date:  2000-06       Impact factor: 5.285

View more
  28 in total

Review 1.  Mesenchymal stem cells in joint disease and repair.

Authors:  Frank Barry; Mary Murphy
Journal:  Nat Rev Rheumatol       Date:  2013-07-23       Impact factor: 20.543

2.  Runx regulation of sphingolipid metabolism and survival signaling.

Authors:  Anna Kilbey; Anne Terry; Alma Jenkins; Gillian Borland; Qifeng Zhang; Michael J O Wakelam; Ewan R Cameron; James C Neil
Journal:  Cancer Res       Date:  2010-06-29       Impact factor: 12.701

3.  ETV6/RUNX1 abrogates mitotic checkpoint function and targets its key player MAD2L1.

Authors:  G Krapf; U Kaindl; A Kilbey; G Fuka; A Inthal; R Joas; G Mann; J C Neil; O A Haas; E R Panzer-Grümayer
Journal:  Oncogene       Date:  2010-03-01       Impact factor: 9.867

4.  RUNX2 transcription factor regulates gene expression in luteinizing granulosa cells of rat ovaries.

Authors:  Eun-Sil Park; Anna-Karin Lind; Pernilla Dahm-Kähler; Mats Brännström; Martha Z Carletti; Lane K Christenson; Thomas E Curry; Misung Jo
Journal:  Mol Endocrinol       Date:  2010-03-02

5.  RGC-32 is a novel regulator of the T-lymphocyte cell cycle.

Authors:  Cosmin A Tegla; Cornelia D Cudrici; Vinh Nguyen; Jacob Danoff; Adam M Kruszewski; Dallas Boodhoo; Armugam P Mekala; Sonia I Vlaicu; Ching Chen; Violeta Rus; Tudor C Badea; Horea Rus
Journal:  Exp Mol Pathol       Date:  2015-03-11       Impact factor: 3.362

6.  Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis.

Authors:  Sanjeev K Baniwal; Omar Khalid; Yankel Gabet; Ruchir R Shah; Daniel J Purcell; Deepak Mav; Alice E Kohn-Gabet; Yunfan Shi; Gerhard A Coetzee; Baruch Frenkel
Journal:  Mol Cancer       Date:  2010-09-23       Impact factor: 27.401

7.  Epigenetic modifications induced by RGC-32 in colon cancer.

Authors:  Sonia I Vlaicu; Cosmin A Tegla; Cornelia D Cudrici; Matthew Fosbrink; Vingh Nguyen; Philippe Azimzadeh; Violeta Rus; Hegang Chen; Petru A Mircea; Abulkalam Shamsuddin; Horea Rus
Journal:  Exp Mol Pathol       Date:  2009-10-31       Impact factor: 3.362

Review 8.  The RUNX family in breast cancer: relationships with estrogen signaling.

Authors:  N-O Chimge; B Frenkel
Journal:  Oncogene       Date:  2012-10-08       Impact factor: 9.867

9.  The osteogenic transcription factor runx2 controls genes involved in sterol/steroid metabolism, including CYP11A1 in osteoblasts.

Authors:  Nadiya M Teplyuk; Ying Zhang; Yang Lou; John R Hawse; Mohammad Q Hassan; Viktor I Teplyuk; Jitesh Pratap; Mario Galindo; Janet L Stein; Gary S Stein; Jane B Lian; Andre J van Wijnen
Journal:  Mol Endocrinol       Date:  2009-04-02

10.  Runt-related transcription factor 1 regulates luteinized hormone-induced prostaglandin-endoperoxide synthase 2 expression in rat periovulatory granulosa cells.

Authors:  Jing Liu; Eun-Sil Park; Misung Jo
Journal:  Endocrinology       Date:  2009-04-02       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.